Research Repository

Angiogenesis inhibitors and the need for anti-angiogenic therapeutics

Dass, Crispin R and Tran, T. M. N and Choong, Peter F. M (2007) Angiogenesis inhibitors and the need for anti-angiogenic therapeutics. Journal of Dental Research, 86 (10). pp. 927-936. ISSN 0022-0345

Full text for this resource is not available from the Research Repository.

Abstract

Angiogenesis is the formation of new blood vessels from pre-existing vessels to form capillary networks, which, among other diseases, such as diabetic retinopathy and macular degeneration, is particularly important for tumor growth and metastasis. Thus, depriving a tumor of its vascular supply by means of anti-angiogenic agents has been of great interest since its proposal in the 1970s. This review looks at the common angiogenic inhibitors (angiostatin, endostatin, maspin, pigment epithelium-derived factor, bevacizumab and other monoclonal antibodies, and zoledronic acid) and their current status in clinical trials.

Item Type: Article
Uncontrolled Keywords: ResPubID18883, angiogenesis, therapy, blood vessel, cancer, vasculature
Subjects: FOR Classification > 1102 Cardiovascular Medicine and Haematology
Faculty/School/Research Centre/Department > School of Biomedical and Health Sciences
Depositing User: VUIR
Date Deposited: 04 May 2012 04:12
Last Modified: 03 Feb 2015 00:20
URI: http://vuir.vu.edu.au/id/eprint/3233
DOI: 10.1177/154405910708601005
ePrint Statistics: View download statistics for this item
Citations in Scopus: 22 - View on Scopus

Repository staff only

View Item View Item

Search Google Scholar